Verona Pharma plc
VRNA
$105.27
$0.070.07%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 35.28% | -158.50% | -218.96% | -203.27% | -142.89% |
| Total Depreciation and Amortization | 24.22% | 39.21% | 56.28% | 62.42% | 44.05% |
| Total Amortization of Deferred Charges | 560.85% | 991.41% | 1,269.83% | 487.43% | 401.25% |
| Total Other Non-Cash Items | 146.54% | 267.36% | 91.18% | 9.10% | 101.11% |
| Change in Net Operating Assets | -307.76% | -92.73% | 212.14% | 326.25% | 300.29% |
| Cash from Operations | -34.64% | -106.98% | -143.33% | -118.19% | -1.73% |
| Capital Expenditure | -2,277.78% | -6,768.75% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -2,277.78% | -6,768.75% | -- | -- | -- |
| Total Debt Issued | -18.99% | 753.30% | 216.47% | 656.21% | 656.21% |
| Total Debt Repaid | 100.00% | -- | -- | -793.26% | -793.26% |
| Issuance of Common Stock | 12,885.65% | 10,755.57% | 74.83% | -92.51% | -99.59% |
| Repurchase of Common Stock | -1,179.93% | -1,425.92% | -229.65% | -578.30% | -200.40% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -104.72% | 24,953.46% | 775,808.33% | 47,586.22% | 1,099.03% |
| Cash from Financing | -43.83% | 1,169.45% | 170.04% | 152.74% | -11.03% |
| Foreign Exchange rate Adjustments | 13,809.09% | -9.53% | -100.85% | 5.82% | -101.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -75.04% | 501.10% | 191.24% | 206.54% | -15.92% |